Prostate Cancer

The combination of lenalidomide and docetaxel for treatment of CRPC failed to produce results in the large phase III MAINSAIL trial.

Men with prostate cancer now have an array of treatments, which was not the case a decade ago.

Not all intermediate-risk prostate cancer patients benefit from the addition of androgen deprivation therapy to radiation therapy.

The investigational compound tasquinimod significantly postpones disease progression and increases PFS in men with minimally symptomatic, metastatic CRPC.

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.

Dr. Christopher Logothetis, from the MD Anderson Cancer Center, Discusses Prostate Cancer Therapy

Dr. Leonard Gomella, from Kimmel Cancer Center, Discusses Androgen-Deprivation Therapy

Delivering higher doses of external beam radiation in a shorter period of time was as effective as conventional radiation in preventing treatment failure in men with intermediate- to high-risk prostate cancer.

Radium-223, an alpha-emitting radiopharmaceutical, has been shown to improve overall survival (OS) in men with metastatic castrationresistant prostate cancer (mCRPC) in an interim analysis of the ALSYMPCA trial.

Middle-aged men taking a class of drugs called statins to reduce cholesterol levels were shown to have reduced the risk of mortality due to prostate cancer by approximately 50%, according to a new study...

Dr. Oliver Sartor, from Tulane Cancer Center, Describes Patients in the ALSYMPCA Radium-223 Trial

The rate of hospitalization in older men within 30 days of a prostate biopsy is more than double that occurring in a control population not undergoing a biopsy.

A single dose of radiotherapy and a single injection of ibandronate provided similar pain relief from bone metastases in men with metastatic prostate cancer.

Physicians and patients with castration-resistant prostate cancer (CRPC) have an increasing number of treatment options that improve outcomes.

New data support a potential link between early-onset androgenic alopecia and the development of prostate cancer.

After decades of use, a routine test used for diagnosing prostate cancer has come under fire after a government panel questioned its safety.

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability

Dr. Daniel Petrylak from Herbert Irving Comprehensive Cancer Center Discusses Sequencing Prostate Cancer Therapies

The impact that the tumor microenvironment has on the survival and growth of cancer cells is becoming increasingly well defined on several fronts.

Dr. Oliver Sartor from Tulane Cancer Center Discusses Prostate Cancer Drug Combinations

Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process

Dr. Oliver Sartor from Tulane Cancer Center Discusses the Novel Agent Radium-223

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Inhibiting the RANKL protein, which is involved in bone metabolism, can delay the onset of the bone metastases in men with castration-resistant prostate cancer.

Two trials are underway that not only address bone-related issues but might improve survival rates for patients.